These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34313026)

  • 21. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
    Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
    Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
    Chen S; Liang Y; Feng Z; Wang M
    BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
    Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
    N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
    Ma F; Yan M; Li W; Ouyang Q; Tong Z; Teng Y; Wang Y; Wang S; Geng C; Luo T; Zhong J; Zhang Q; Liu Q; Zeng X; Sun T; Mo Q; Liu H; Cheng Y; Cheng J; Wang X; Nie J; Yang J; Wu X; Wang X; Li H; Ye C; Dong F; Wu S; Zhu X; Xu B;
    BMJ; 2023 Oct; 383():e076065. PubMed ID: 37907210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
    Bergh J; Bondarenko IM; Lichinitser MR; Liljegren A; Greil R; Voytko NL; Makhson AN; Cortes J; Lortholary A; Bischoff J; Chan A; Delaloge S; Huang X; Kern KA; Giorgetti C
    J Clin Oncol; 2012 Mar; 30(9):921-9. PubMed ID: 22331954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
    Ribelles N; Jerez JM; Rodriguez-Brazzarola P; Jimenez B; Diaz-Redondo T; Mesa H; Marquez A; Sanchez-Muñoz A; Pajares B; Carabantes F; Bermejo MJ; Villar E; Dominguez-Recio ME; Saez E; Galvez L; Godoy A; Franco L; Ruiz-Medina S; Lopez I; Alba E
    Eur J Cancer; 2021 Feb; 144():224-231. PubMed ID: 33373867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
    Mendes D; Alves C; Afonso N; Cardoso F; Passos-Coelho JL; Costa L; Andrade S; Batel-Marques F
    Breast Cancer Res; 2015 Nov; 17():140. PubMed ID: 26578067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers.
    Zelnak AB; Styblo TM; Rizzo M; Gabram SG; Wood WC; Harichand-Herdt S; Kim S; Liu Y; O'Regan RM;
    Clin Breast Cancer; 2013 Jun; 13(3):173-9. PubMed ID: 23332349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran.
    Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
    Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer.
    Camerini A; Donati S; Viacava P; Siclari O; Puccetti C; Tartarelli G; Valsuani C; De Luca F; Martini L; Cavazzana A; Amoroso D
    J Exp Clin Cancer Res; 2011 Apr; 30(1):38. PubMed ID: 21481270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
    Mavratzas A; Baek S; Gerber B; Schmidt M; Moebus V; Foerster F; Grischke EM; Fasching P; Strumberg D; Solomayer E; Klare P; Windemuth-Kieselbach C; Hartmann S; Schneeweiss A; Marmé F
    Breast; 2019 Jun; 45():22-28. PubMed ID: 30822621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
    Coté D; Eustace A; Toomey S; Cremona M; Milewska M; Furney S; Carr A; Fay J; Kay E; Kennedy S; Crown J; Hennessy B; Madden S
    PLoS One; 2018; 13(8):e0200996. PubMed ID: 30071039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
    Dong L; Zhu LN; Xie BJ; Li JB; Ding T; Jiang YF; Zhu ZN
    Pharmacotherapy; 2019 Dec; 39(12):1126-1136. PubMed ID: 31692005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.